 | • レポートコード：MRC2304L019 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に419.9億ドルであった世界のヒトインスリン製剤市場規模が、2022年に462.2億ドルへと拡大し、その後CAGR 10.31％で成長して2027年までに756.8億ドルに達すると予測しています。当書は、ヒトインスリン製剤の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品タイプ別（基本/長時間作用型インスリン、バイオシミラーインスリン、併用インスリン、即効型インスリン、従来型ヒトインスリン）分析、ブランド別（ヒューマログ、ランタス、ノボラピッド）分析、用途別（1型糖尿病、2型糖尿病）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Albireo Pharma, Inc.、B. Braun Melsungen AG、Becton, Dickinson, and Company、Biocon Limited、Eli Lilly and Company、Gan & Lee Pharmaceuticals Co., Ltd.、Gulf Pharmaceutical Industries、Medtronic PLCなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のヒトインスリン製剤市場規模：製品タイプ別 - 基本/長時間作用型インスリンの市場規模 - バイオシミラーインスリンの市場規模 - 併用インスリンの市場規模 - 即効型インスリンの市場規模 - 従来型ヒトインスリンの市場規模 ・世界のヒトインスリン製剤市場規模：ブランド別 - ヒューマログの市場規模 - ランタスの市場規模 - ノボラピッドの市場規模 ・世界のヒトインスリン製剤市場規模：用途別 - 1型糖尿病における市場規模 - 2型糖尿病における市場規模 ・世界のヒトインスリン製剤市場規模：地域別 - 南北アメリカのヒトインスリン製剤市場規模 アメリカのヒトインスリン製剤市場規模 カナダのヒトインスリン製剤市場規模 ブラジルのヒトインスリン製剤市場規模 ... - アジア太平洋のヒトインスリン製剤市場規模 日本のヒトインスリン製剤市場規模 中国のヒトインスリン製剤市場規模 インドのヒトインスリン製剤市場規模 韓国のヒトインスリン製剤市場規模 台湾のヒトインスリン製剤市場規模 ... - ヨーロッパ/中東/アフリカのヒトインスリン製剤市場規模 イギリスのヒトインスリン製剤市場規模 ドイツのヒトインスリン製剤市場規模 フランスのヒトインスリン製剤市場規模 ロシアのヒトインスリン製剤市場規模 ... - その他地域のヒトインスリン製剤市場規模 ・競争状況 ・企業情報 |
The Global Human Insulin Drugs Market size was estimated at USD 41.99 billion in 2021 and expected to reach USD 46.22 billion in 2022, and is projected to grow at a CAGR 10.31% to reach USD 75.68 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Human Insulin Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product Type, the market was studied across Basal or Long-acting Insulins, Biosimilar Insulins, Combination Insulins, Fast-acting Insulins, and Traditional Human Insulins.
Based on Brands, the market was studied across Humalog, Lantus, and NovoRapid.
Based on Application, the market was studied across Type 1 Diabetes and Type 2 Diabetes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Human Insulin Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Human Insulin Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Human Insulin Drugs Market, including Albireo Pharma, Inc., B. Braun Melsungen AG, Becton, Dickinson, and Company, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co., Ltd., Gulf Pharmaceutical Industries, Medtronic PLC, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SEDICO Co., Tonghua Dongbao Pharmaceutical Co., Ltd., Wockhardt Limited, and Ypsomed AG.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Human Insulin Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Insulin Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Insulin Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Human Insulin Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Human Insulin Drugs Market?
6. What is the market share of the leading vendors in the Global Human Insulin Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Human Insulin Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of dibetic patient all over the globe
5.1.1.2. Significant growth of geriatric and obese population
5.1.1.3. Adoption of different drug delivery methods
5.1.2. Restraints
5.1.2.1. High cost associated with human insulin drugs
5.1.3. Opportunities
5.1.3.1. New regulations for insulin biosimilars
5.1.3.2. Ongoing investments in R&D of human insulin drugs
5.1.4. Challenges
5.1.4.1. Concern associated with severe health problems
5.1.4.2. Stringent regulatory norms for approvals
5.2. Cumulative Impact of COVID-19
6. Human Insulin Drugs Market, by Product Type
6.1. Introduction
6.2. Basal or Long-acting Insulins
6.3. Biosimilar Insulins
6.4. Combination Insulins
6.5. Fast-acting Insulins
6.6. Traditional Human Insulins
7. Human Insulin Drugs Market, by Brands
7.1. Introduction
7.2. Humalog
7.3. Lantus
7.4. NovoRapid
8. Human Insulin Drugs Market, by Application
8.1. Introduction
8.2. Type 1 Diabetes
8.3. Type 2 Diabetes
9. Americas Human Insulin Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Human Insulin Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Human Insulin Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Albireo Pharma, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. B. Braun Melsungen AG
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Becton, Dickinson, and Company
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Biocon Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Eli Lilly and Company
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Gan & Lee Pharmaceuticals Co., Ltd.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Gulf Pharmaceutical Industries
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Medtronic PLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Novo Nordisk A/S
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Pfizer Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Sanofi S.A.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. SEDICO Co.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Tonghua Dongbao Pharmaceutical Co., Ltd.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Wockhardt Limited
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Ypsomed AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing